MedTrace Logo

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

NCT04692389 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-02-08

No results posted yet for this study

Summary

Testing the efficacy of the Jalosome® Soothing gel in 2 or 3 grade radiodermatitis healing in oncological patients.

The investigators would like to know also the efficacy of the device on quality of life and pain.

Conditions

Interventions

DEVICE

Jalosome soothing gel

This study has not got other intervention

Sponsors & Collaborators

  • Oncology Institute of Southern Switzerland

    collaborator OTHER

  • Welcare Industries SpA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-02-01
Completion
2023-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04692389 on ClinicalTrials.gov